Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment

With this protocol the Investigators will test the hypotheses that a) there is a correlation
between airway and pulmonary vascular endothelial function within the current smoker and
non-smoker groups, and b) ICS treatment improves airway and pulmonary vascular endothelial
function in the current smoker group.

Fifteen healthy current smokers with a >10 pack-year history of smoking and 15 healthy
never-smokers will be enrolled. Males and females between 25 and 75 years of age will be
recruited There will be 1-4 visits to the laboratory (one for non-smokers, 4 for smokers).
All subjects will have the first visit. Current smokers will have 3 additional visits.
Current smokers will be asked not to smoke before coming to the laboratory on the 3 study
days. All subjects will be instructed to abstain from ingesting alcoholic beverages, coffee
or caffeinated drinks for at least 12 hours the night before each study day. The subjects
will also be instructed not to use PDE5 inhibitors for 24 hours before coming to the
laboratory. On each study day, the protocol will start at the same time (in the morning).

Inclusion Criteria:

- Fifteen healthy current smokers with a >10 pack-year history of smoking and 15
healthy never-smokers will be enrolled. Males and females between 25 and 75 years of
age will be recruited.

Exclusion Criteria:

- Women of childbearing potential who do not use accepted birth control measures;
pregnant and breast feeding women

- Cardiovascular disease and/or use of cardiovascular medications

- Subjects with known beta-adrenergic agonist intolerance

- A physician diagnosis of chronic airway disease (asthma, COPD, bronchiectasis, cystic
fibrosis)

- Acute respiratory infection within four weeks prior to the study

- Use of any airway medication

- Abnormal pulmonary function